Research in the area of pharmaceutical cocrystals has sparked much interest in recent years.  Cocrystallization of an active pharmaceutical ingredient (API) with a cocrystal former (a coformer) generates a new solid phase, which may have improved properties over existing solid phases of the API. Our research focuses on the API pyrazinamide (PZA), an antibiotic used in the treatment of tuberculosis.  We will present a series of PZA cocrystals that have been prepared employing substituted benzamide and benzoic acid coformers (substituent group = -OH, -NH2, -NO2). Synthesis of the cocrystals was achieved by solvent-drop grinding, slow evaporation, slurry and the melt.  Characterization was accomplished using PXRD, DSC, TGA and single crystal X-ray crystallography, when possible.  The impact of the electronic effect of the coformer substituent on cocrystal formation will be addressed.

Crystal engineering of new cocrystals of pyrazinamide using benzamides and benzoic acids

243rd National Meeting (2012)

The official archive and repository for all ACS Meetings & Expositions abstracts and select posters or presentations.